Phase 3 Study Comparing Pomalidomide and Dexamethasone w/Without Daratumumab in Subjects With Relapsed or Refractory MM Who Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Daratumumab (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms APOLLO
- 08 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
- 28 Jun 2017 Status changed from not yet recruiting to recruiting.
- 27 May 2017 Status changed from planning to recruiting.